Display options
Cite
Guadagno E, Vitiello M, Francesca P, et al. PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget. 2017;8(35):59282-59300doi: 10.18632/oncotarget.19546.
Guadagno, E., Vitiello, M., Francesca, P., Calì, G., Caponnetto, F., Cesselli, D., Camorani, S., Borrelli, G., Califano, M., Cappabianca, P., Arra, C., Crescenzi, E., Cerchia, L., De Caro, M. L. D. B., & Fedele, M. (2017). PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget, 8(35), 59282-59300. https://doi.org/10.18632/oncotarget.19546
Guadagno, Elia, et al. "PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype." Oncotarget vol. 8,35 (2017): 59282-59300. doi: https://doi.org/10.18632/oncotarget.19546
Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, Camorani S, Borrelli G, Califano M, Cappabianca P, Arra C, Crescenzi E, Cerchia L, De Caro MLDB, Fedele M. PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. Oncotarget. 2017 Jul 25;8(35):59282-59300. doi: 10.18632/oncotarget.19546. eCollection 2017 Aug 29. PMID: 28938636; PMCID: PMC5601732.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jul 25;8(35):59282-59300. doi: 10.18632/oncotarget.19546. eCollection 2017 Aug 29.

PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype.

Oncotarget

Elia Guadagno, Michela Vitiello, Paola Francesca, Gaetano Calì, Federica Caponnetto, Daniela Cesselli, Simona Camorani, Giorgio Borrelli, Marialuisa Califano, Paolo Cappabianca, Claudio Arra, Elvira Crescenzi, Laura Cerchia, Maria Laura Del Basso De Caro, Monica Fedele

Affiliations

  1. Department of Advanced Biomedical Sciences, Pathology Section, University of Naples Federico II, 80131 Naples, Italy.
  2. Institute of Experimental Endocrinology and Oncology (IEOS) "Gaetano Salvatore", National Council of Research, 80131 Naples, Italy.
  3. Department of Medical and Biological Sciences, University of Udine, 33100 Udine, Italy.
  4. Division of Neurosurgery, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, 80131 Naples, Italy.
  5. Department of Experimental Oncology, National Cancer Institute "Fondazione Giovanni Pascale", IRCCS, 80131 Naples, Italy.

PMID: 28938636 PMCID: PMC5601732 DOI: 10.18632/oncotarget.19546

Abstract

Glioblastoma (GBM), the most malignant of the brain tumors, has been classified on the basis of molecular signature into four subtypes: classical, mesenchymal, proneural and neural, among which the mesenchymal and proneural subtypes have the shortest and longest survival, respectively. Here we show that the transcription factor

Keywords: PATZ1; biomarker; glioma; glioma stem cells; tumor heterogeneity

Conflict of interest statement

CONFLICTS OF INTEREST No conflict of interests to declare.

References

  1. Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
  2. Nature. 2012 Aug 23;488(7412):522-6 - PubMed
  3. Oncotarget. 2015 Mar 10;6(7):5310-23 - PubMed
  4. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  5. Cell Death Differ. 2012 Apr;19(4):703-12 - PubMed
  6. Crit Rev Oncog. 2014;19(5):327-36 - PubMed
  7. Genome Res. 2002 Sep;12(9):1408-17 - PubMed
  8. Sci Rep. 2016 Feb 09;6:21557 - PubMed
  9. Cell Cycle. 2009 Sep 15;8(18):2936-44 - PubMed
  10. Nature. 2013 Sep 19;501(7467):328-37 - PubMed
  11. Methods. 2001 Dec;25(4):402-8 - PubMed
  12. J Pathol. 2008 May;215(1):39-47 - PubMed
  13. Nat Rev Cancer. 2006 Jun;6(6):425-36 - PubMed
  14. Anat Rec (Hoboken). 2013 Dec;296(12 ):1850-6 - PubMed
  15. Anticancer Agents Med Chem. 2016;16(1):59-74 - PubMed
  16. Cancer Cell. 2006 Mar;9(3):157-73 - PubMed
  17. J Cell Physiol. 2013 Mar;228(3):646-53 - PubMed
  18. Cell Stem Cell. 2009 Jun 5;4(6):568-80 - PubMed
  19. Oncotarget. 2016 Sep 13;7(37):59158-59172 - PubMed
  20. Oncotarget. 2016 Aug 9;7(32):52255-52269 - PubMed
  21. Cancer Res. 2007 Jun 15;67(12):5635-42 - PubMed
  22. Acta Neuropathol. 2007 Aug;114(2):97-109 - PubMed
  23. BMC Cancer. 2010 Aug 24;10 :454 - PubMed
  24. PLoS One. 2013 May 07;8(5):e62857 - PubMed
  25. Sci Rep. 2014 Dec 17;4:7519 - PubMed
  26. Nature. 2008 Oct 23;455(7216):1061-8 - PubMed
  27. Sci Rep. 2016 Apr 29;6:25268 - PubMed
  28. Cell Stem Cell. 2014 Aug 7;15(2):185-98 - PubMed
  29. Mol Ther. 2014 Apr;22(4):828-41 - PubMed
  30. Nature. 2004 Nov 18;432(7015):396-401 - PubMed
  31. Cancer Ther. 2008;6(B):865-876 - PubMed
  32. Cell Death Dis. 2013 Dec 12;4:e963 - PubMed
  33. EMBO Rep. 2014 Mar;15(3):244-53 - PubMed
  34. Oncogene. 2008 May 1;27(20):2897-909 - PubMed
  35. Mol Cancer. 2006 Dec 02;5:67 - PubMed
  36. Brief Funct Genomic Proteomic. 2007 Mar;6(1):8-18 - PubMed
  37. Oncotarget. 2015 Mar 20;6(8):6267-80 - PubMed
  38. Stem Cells Dev. 2014 May 15;23 (10 ):1062-73 - PubMed
  39. Genes Dev. 2012 Jun 1;26(11):1247-62 - PubMed
  40. Glia. 2011 Apr;59(4):590-602 - PubMed
  41. Neuro Oncol. 2013 Jul;15(7):829-39 - PubMed
  42. Endocrinology. 2012 Jan;153(1):522-34 - PubMed
  43. Mol Cell Biol. 2015 May;35(10):1741-53 - PubMed
  44. Stem Cells. 2014 May;32(5):1239-53 - PubMed
  45. Cancer Cell. 2010 Jan 19;17(1):98-110 - PubMed
  46. Acta Biochim Biophys Sin (Shanghai). 2008 Apr;40(4):289-96 - PubMed
  47. PLoS One. 2014 Nov 12;9(11):e112582 - PubMed

Publication Types